Storer BE - Search Results

1

Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.

Brown RR, Lee CM, Kohler PC, Hank JA, Storer BE, Sondel PM. Brown RR, et al. Among authors: storer be. Cancer Res. 1989 Sep 1;49(17):4941-4. Cancer Res. 1989. PMID: 2788032

2

Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.

Schiller JH, Storer B, Witt PL, Nelson B, Brown RR, Horisberger M, Grossberg S, Borden EC. Schiller JH, et al. Cancer Res. 1990 Aug 1;50(15):4588-94. Cancer Res. 1990. PMID: 2114942

3

The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.

Albertini MR, Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Bechhofer R, Storer B, Sondel PM. Albertini MR, et al. Cancer. 1990 Dec 15;66(12):2457-64. doi: 10.1002/1097-0142(19901215)66:12<2457::aid-cncr2820661203>3.0.co;2-l. Cancer. 1990. PMID: 2249185 Clinical Trial.

4

Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.

Kohler PC, Hank JA, Moore KH, Storer B, Bechhofer R, Hong R, Sondel PM. Kohler PC, et al. Cancer Invest. 1989;7(3):213-23. doi: 10.3109/07357908909039840. Cancer Invest. 1989. PMID: 2790538 Clinical Trial.

5

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

Goldstein D, Sosman JA, Hank JA, Weil-Hillman G, Moore KH, Borchert A, Bechhofer R, Storer B, Kohler PC, Levitt D, et al. Goldstein D, et al. Cancer Res. 1989 Dec 1;49(23):6832-9. Cancer Res. 1989. PMID: 2819723

6

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM. Sosman JA, et al. J Natl Cancer Inst. 1988 Mar 2;80(1):60-3. doi: 10.1093/jnci/80.1.60. J Natl Cancer Inst. 1988. PMID: 3257526

7

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

Hank JA, Kohler PC, Weil-Hillman G, Rosenthal N, Moore KH, Storer B, Minkoff D, Bradshaw J, Bechhofer R, Sondel PM. Hank JA, et al. Cancer Res. 1988 Apr 1;48(7):1965-71. Cancer Res. 1988. PMID: 3258180

8

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B. Sondel PM, et al. Cancer Res. 1988 May 1;48(9):2561-7. Cancer Res. 1988. PMID: 3258545

9

The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.

Rosenthal NS, Hank JA, Kohler PC, Minkoff DZ, Moore KH, Bechhofer R, Hong R, Storer B, Sondel PM. Rosenthal NS, et al. J Biol Response Mod. 1988 Apr;7(2):123-39. J Biol Response Mod. 1988. PMID: 3258904

10

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.

Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, Sondel PM. Sosman JA, et al. J Natl Cancer Inst. 1988 Nov 16;80(18):1451-61. doi: 10.1093/jnci/80.18.1451. J Natl Cancer Inst. 1988. PMID: 3263508 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

404 results

Search Page

Filters